"I was shocked to find out that the CMS proposed National Coverage Determination (NCD) severely restricts Medicare coverage for a whole class of Alzheimers treatments, including the recently FDA-approved Aduhelm, to only cover these drugs in CMS-approved clinical trials."Read on Twitter
Here are other recent tweets from Cathy McMorris Rodgers:
"It also excludes those with Down Syndrome from participating in covered trials, even though Alzheimers may affect greater than 90 percent of those with Down Syndrome over the age of 60. This is wrong."Read on Twitter
"@RepKevinBrady, @RepGuthrie, @VernBuchanan and I sent a letter to HHS @SecBecerra urging him to abandon and re-propose access to FDA-approved Alzheimers treatments for a broader population of Medicare beneficiaries. Read:republicans-energycommerce.house.gov/news/gop-to-hh"Read on Twitter
"Im not convinced that a brand-new agency like ARPA-H will be able to overcome the institutional, cultural, and bureaucratic barriers that are present at our federal scientific agencies." on Feb. 8Read on Twitter